| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Property and equipment, net | - | 0 | ||
| Operating lease right-of-use assets, net | - | 0 | ||
| Cash | 85,571 | 459 | ||
| Other current assets | - | 1,300 | ||
| Total current assets | 85,571 | 1,759 | ||
| Other assets | 50,000 | 50,000 | ||
| Total assets | 135,571 | 51,759 | ||
| Total liabilities | 6,052,780 | 5,489,388 | ||
| Common stock, 0.0001 par value, 100,000,000 shares authorized 1,605,377 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 161 | 161 | ||
| Additional paid-in capital | 11,462,608 | 11,363,685 | ||
| Accumulated deficit | -17,379,978 | -16,801,475 | ||
| Total stockholders deficit | -5,917,209 | -5,437,629 | ||
| Total liabilities and stockholders deficit | 135,571 | 51,759 | ||
Sigyn Therapeutics, Inc. (SIGY)
Sigyn Therapeutics, Inc. (SIGY)